Encephalopathy associated with propofol infusion syndrome

A case report

Xiaolin Li, MD\textsuperscript{a}, Zhangning Zhao, MD\textsuperscript{b}, Xiaomin Liu, MD\textsuperscript{b}, Gaoting Ma, MD\textsuperscript{b}, Mei-Jia Zhu, MD\textsuperscript{b},* 

Abstract

Introduction: Propofol infusion syndrome (PRIS) is a rare but potentially fatal complication of propofol infusion. It is clinically characterized by metabolic acidosis, refractory bradycardia, rhabdomyolysis, renal failure, hyperlipidemia, and hepatomegaly. Brain lesion was only reported once in a pediatric patient. We present the 1st adult case with colon polyp and cancer who was diagnosed with PRIS. Her brain magnetic resonance imaging (MRI) and computed tomography (CT) scans reveal prominent bilateral brain lesions, matching with the proposed pathophysiologic mechanism of the syndrome. The patient received prompt acidosis correction and cardiorespiratory support. At last, she died from refractory circulatory failure.

Conclusion: It may be necessary to order a prompt neuroimaging examination in patients suspected with PRIS to judge whether brain lesions exist or not.

Abbreviations: CT = computed tomography, MRI = magnetic resonance imaging, PRIS = propofol infusion syndrome.

Keywords: encephalopathy, magnetic resonance imaging, propofol, propofol infusion syndrome

1. Introduction

Propofol infusion syndrome (PRIS) is a rare but often fatal complication of propofol infusion when the rate exceeds 4 mg/kg hour and/or the duration of use exceeds 48 hours. The syndrome is clinically characterized by metabolic acidosis, refractory bradycardia, rhabdomyolysis, renal failure, hyperlipidemia, and hepatomegaly.\textsuperscript{1–10} Occurrence of brain lesions, however, receives little attention. Herein, we present an adult patient with PRIS showing bilateral symmetric brain lesions on computed tomography (CT) and magnetic resonance imaging (MRI), promoting the necessity of neuroimaging in such patients. This study was approved by the local ethics committee, and a written informed consent has been obtained from relatives for publication of this case report and any accompanying image.

2. Case presentation

A 30-year-old woman with colon polyp and cancer and a family history of this disease underwent a laparoscopic surgery under sedation with persistent propofol infusion at an average hourly rate of 3.3 mg/kg (120 mg propofol IV for anesthesia induction). The procedure went well until a mild unpredictable hypotension (90/60 mmHg) was noted 3.5 hours later. Dopamine infusion was initiated for blood pressure support. An immediate capillary glucose measurement was 3.2 mmol/l. Following arterial blood gas measurement revealed a metabolic acidosis (pH 6.91, pCO\textsubscript{2} 44 mmHg, pO\textsubscript{2} 104 mmHg, base excess –22.4 mmol/L, lactate 15 mmol/L, blood glucose 2.1 mmol/L). Therefore, the patient was treated with sodium carbonate intravenously. Arterial blood gas remeasurement after 15 minutes revealed a pH of 7.28, a lactate of 15 mmol/L, a base excess of –3.1 mmol/L, and a blood glucose of 1.3 mmol/L (normal 3.9–11.1). The patient was immediately given 40 mL of 50% glucose IV followed by constant 5% glucose infusion intravenously. Intermittent arterial blood gas measurement in the next few hours showed pH ranging from 7.06 to 7.49, blood glucose ranging from 11.0 to 12.2 mmol/L, and a persistent high level of lactate equal to or greater than 8.8 mmol/L. The propofol infusion was ceased 6 hours after its onset. The patient remained in an unresponsive state for 3 hours since the propofol discontinuation. Neurological examinations at the moment revealed a gazing toward right and bilateral positive Babinski signs. Therefore, a brain damage was suspected.

Following MRI of the head demonstrated hypointense signals of the basal ganglia, temporal lobe, and cerebellum bilaterally on diffusion-weighted image (Fig. 1A–C) and a corresponding hypointense signals on T1-weighted image (Fig. 1D). And a CT scan of the head revealed prominent decreased attenuation in the
corresponding basal ganglia (Fig. 1E). A repeat CT scan after 3
days revealed bleeding of the left caudate nucleus (Fig. 1F).
To receive better medical therapy for cerebral resuscitation, the
patient was transferred to our hospital. Creatine kinase 10 hours
after the event onset increased to 1644 IU/L (normal 30–135).
Two days later an elevated brain natriuretic peptide (1270 pg/mL,
normal <100) was noted, suggesting a heart failure. Cardiac
monitoring revealed neither arrhythmia nor hypoxia throughout
the procedure. Combination of the lactic acidosis, the elevated
creatine kinase level and the cardiac insufficiency in the context of
propofol anesthesia suggested PRIS. Considering the probable
association between PRIS and mtDNA mutations proposed
before,[11] a whole mitochondrial DNA sequencing with Sanger
method was conducted and revealed no abnormalities. The
patient’s relatives refused further investigations. Unfortunately,
the patient died due to refractory circulatory failure 16 days
following admission.

3. Discussion
Propofol is widely used in anesthesia and intensive care due to its
short-acting pharmacokinetics, making continuous intravenous
infusion easily and facilitating the weaning of patients from
ventilator support. However, many serious adverse effects (so
called PRIS[3]) have been reported to be associated with propofol
infusion since the 1st case of death,[3] including refractory bradycardia, metabolic acidosis, cardiac failure, rhabdomyolysis,
renal failure, and hepatomegaly.[11–10] In our patient, metabolic acidosis, cardiac failure, and mild rhabdomyolysis
were present during or after the propofol infusion, which cannot
be attributed to other causes. The diagnosis of PRIS was made.
Although the mechanisms behind this syndrome have not been
fully understood, it is generally accepted that propofol-induced
inhibition of intracellular energy production could account for
PRIS.[10] In 2001, elevated total carnitine, C5-acylcarnitine, and
malonylcarnitine were found in a pediatric patient with PRIS.[12]
Malonylcarnitine inhibits the membrane transport protein carni-
tine palmityl transferase I and entry of long-chain acylcarnitine into
mitochondria decreases.[10] Some evidence from animal models
show that propofol directly disrupts electron flow down the
mitochondrial respiratory electron transport chain[13,14] In these
ways, propofol impairs adenosine triphosphate production in the
cell. Thus, tissue with high metabolic activities, such as myocardi-
um and brain are, in theory, more prone to be affected in the clinical
setting. Arrhythmia or cardiac dysfunctions were, as mentioned
above, frequently observed in patients with PRIS, whereas neuroimaging findings were only reported once in a 3-
year-old girl with transient limb weakness by Poretti et al.[15]
possibly because neuroimaging had not been conducted in patients
with nonneurological deficits. MRI of brain in our patient
demonstrates prominent bilateral lesions in basal ganglia,
temporal lobe, and cerebellum. Etiologies for bilateral basal
ganglia MRI abnormalities include hypoxic-ischemic, toxic and
metabolic, infectious, immune-mediated, mitochondrial, and
neurodegenerative disorders.[16,17] Encephalopathy of hypoxic-
ischemic origin could be certainly ruled out in this patient because
of the nearly normal degree of blood oxygen saturation and blood
pressure throughout the procedure. Considering the acute-onset

![Figure 1. Brain magnetic resonance imaging and computed tomography (CT) scans. Diffusion-weighted imaging shows bilateral hyperintensity lesions of basal ganglia (A, arrows), temporal lobe (B, arrows), and cerebellum (C, arrows), with corresponding hypointensity lesions of basal ganglia on T1-weighted image (D, arrow). CT scan shows decreased attenuation of bilateral basal ganglia (E, arrows). And a repeat CT scan 3 days thereafter shows bleeding of the left caudate nucleus (F, arrow).](image-url)
form, an infectious (eg, Creutzfeldt–Jakob disease, flavivirus encephalitides, and toxoplasmosis) or neurodegenerative (eg, Huntington disease, neurodegeneration with brain iron accumulation, and Fahr disease) lesion would be unlikely. A minority of patients with Behçet disease could manifest initially in the central nervous system, commonly involving basal ganglia, but the moderate to strong hyperintense signals on diffusion weighted image argue against the diagnosis. Based on the consideration mentioned above, we suspected a metabolic and toxic etiology. Some toxic poisoning (carbon monoxide, methanol, and cyanide), osmotic myelinolysis, Wernicke encephalopathy, and Leigh disease should be taken into account, but the absence of relevant clinical information make these diagnoses unlikely. Hypoglycemia was a candidate causative factor for the encephalopathy. However, cerebellum is usually unaffected under hypoglycemic status due to the greater activity of the glucose transport mechanisms therein. Moreover, it is unexpected that so short a duration (about 15 minutes) of hypoglycemia could cause so serious brain lesions. For such reasons, we determined the association between the encephalopathy and PRIS.

Some risk factors for PRIS have been proposed, including young age, propofol dosage over 4 to 5 mg/kg per hour, use of duration over 48 hours, critical illness, high fat low carbohydrate intake, inborn error of fatty acid oxidation, and concomitant catecholamine or steroid use. This 30-year-old patient was otherwise healthy except for colon polyp and cancer. No catecholamine or steroid was administered prior to the event. Considering the strong association between PRIS and propofol infusion at doses greater than 4 mg/kg/hour of longer than 48 hours duration, it is confusing that this patient receiving propofol infusion at an average hourly rate of 3.3 mg/kg for about 6 hours could develop the syndrome. We presumed a potential mitochondrial disease in the patient. However, a whole mitochondrial DNA sequencing with Sanger method revealed no abnormalities. Some other predisposing factors might exist and need further investigations.

There is no established standard treatment for PRIS. A sufficient carbohydrate intake might work to prevent PRIS by suppressing the switch to fat metabolism. Wolf et al suggested a carbohydrate intake of 6 to 8 mg/(kg·min) in critically ill children. Early recognition plays an important role in successful management of PRIS. The propofol infusion must be stopped immediately. Then hemodialysis or hemoperfusion combined with cardiopulmonary support is advocated. Hemodialysis or hemofiltration could decrease metabolic acids and lipids in the blood and thus to facilitate maintaining hemodynamic stability and alleviate further fat metabolism. Culp et al reported a successful treatment of PRIS with early circulatory support via use of extracorporeal membrane oxygenation. Despite the correction of acidosis and cardiopulmonary support, our patient had remained in a coma, probably due to the profound brain damage. And she died of refractory circulatory failure ultimately. In contrast, Poretti’s patient who had basal ganglia spared on MRI recovered completely. It is possible that, like observations in hypoglycemic encephalopathy, basal ganglia involvement in PRIS also indicates a poor outcome.

4. Conclusions
We recommend neuroimaging for unresponsive patients with suspected PRIS, because a timely treatment for brain protection may improve the prognosis if brain damage occurs.

References
[1] Kam PC, Cardone D. Propofol infusion syndrome. Anaesthesia 2007;62:690–701.
[2] Parke TJ, Stevens JE, Rice AS, et al. Metabolic acidosis and fatal myocardial failure after propofol infusion in children: five case reports. BMJ 1992;305:613–6.
[3] Bray RJ. Propofol infusion syndrome in children. Paediatr Anaesth 1998;8:491–9.
[4] Hannas JP, Ramundo ML. Rhabdomyolysis and hypoxia associated with prolonged propofol infusion in children. Neurology 1998;50:301–3.
[5] Hatch DJ. Propofol-infusion syndrome in children. Lancet 1999;353:1117–8.
[6] Stelow EB, Johari VP, Smith SA, et al. Propofol-associated rhabdomyolysis with cardiac involvement in adults: chemical and anatomic findings. Clin Chem 2000;46:577–81.
[7] Badr AE, Mychaskiw G, Eichhorn JH. Metabolic acidosis associated with a new formulation of propofol. Anesthesiology 2001;94:536–8.
[8] Cremer OL, Moons KG, Bouman EA, et al. Long-term propofol infusion and cardiac failure in adult head-injured patients. Lancet 2001;357:1117–8.
[9] Casserly B, O’Malhony E, Timm EG, et al. Propofol infusion syndrome: an unusual cause of renal failure. Am J Kidney Dis 2004;44:e98–101.
[10] Diedrich DA, Brown DR. Analytic reviews: propofol infusion syndrome in the ICU. J Intensive Care Med 2011;26:59–72.
[11] Savard M, Dupre N, Turgeon AF, et al. Propofol-related infusion syndrome heralding a mitochondrial disease: case report. Neurology 2013;81:770–1.
[12] Wolf A, Weir P, Segar P, et al. Impaired fatty acid oxidation in propofol infusion syndrome. Lancet 2001;357:606–7.
[13] Branca D, Roberti MS, Lorenzin P, et al. Influence of the anesthetic 2,6-disopropylphenol on the oxidative phosphorylation of isolated rat liver mitochondria. Biochem Pharmacol 1991;42:87–90.
[14] Schenkman KA, Yan S. Propofol impairment of mitochondrial respiration in isolated perfused guinea pig hearts determined by reflectance spectroscopy. Criti Care Med 2000;28:172–7.
[15] Poretti A, Bozemani T, Huxman TA. Neuroimaging findings in pediatric propofol infusion syndrome. Pediatr Neurol 2014;40:431–2.
[16] Zuccoli G, Yannes MP, Nardone R, et al. Bilateral symmetrical basal ganglia and thalamic lesions in children: an update (2015). Neuroradiology 2015;57:973–89.
[17] Polsky HM, Van der Helm P, Beischer A, et al. Acute encephalopathy and PRIS. J Neurosurg 2000;93:699–701.
[18] Boksa P, Van der Helm PM. Acute encephalopathy and PRIS. J Neurosurg 2000;93:699–701.
[19] Mahony E, Timm EG, et al. Propofol infusion syndrome: a review of 30 cases. J Neurosurg Anesthesiol 1999;11:217–82.
[20] Hegde AN, Mohan S, Lath N, et al. Differential diagnosis for bilateral basal ganglia and thalamus. Radiographics 2011;31:3–30.
[21] Hadfield MG, Aydin F, Lipman HR, et al. Neuro-Behcet’s disease. Clin Neuropathol 1997;16:53–60.
[22] Kiessling M, Xie Y, Kleihues P. Regionally selective inhibition of cerebral blood flow and metabolism in experimental autoimmune encephalomyelitis. J Neuroimmunol 1999;122:11–21.
[23] Culp KE, Augostides JG, Ochroch AE, et al. Clinical management of cardiogenic shock associated with prolonged propofol infusion. Anesth Analg 2004;99:221–6.
[24] Machuta AM, Gonano C, Birxan T, et al. Rare but dangerous adverse effects of propofol and thiopental in intensive care. J Trauma 2003;55:643–5.
[25] Finelli PF. Diffusion-weighted MR in hypoglycemic coma. Neurology 2001;57:933.